Zoran Andrić

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Jacek Jassem, Filippo de Marinis, Giuseppe Giaccone et al. · Journal of Thoracic Oncology · 2021 · 202 citations

Medicine, Oncology, Pharmacology +13

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Aaron S. Mansfield, Andrzej Każarnowicz, Nina Karaseva et al. · Annals of Oncology · 2020 · 190 citations · Full text

Medicine, Oncology, Pharmacology +17

Mobile phone use while driving-literary review

Кrsto Lipovac, Miroslav Đerić, Milan Tešić et al. · Transportation Research Part F Traffic Psychology and Behaviour · 2017 · 161 citations

Public Health, Communication, Literary Studies +13

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

David R. Spigel, Filippo de Marinis, Giuseppe Giaccone et al. · Annals of Oncology · 2019 · 144 citations

Medicine, Oncology, Pharmacology +11